This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
OPKO's BioReference Laboratories Widens COVID-19 Testing (Revised)
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
OPKO's BioReference Laboratories Offers COVID-19 Testing (Revised)
by Zacks Equity Research
OPKO's (OPK) BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties in New Jersey.
OPKO's BioReference Laboratories Widens COVID-19 Testing
by Zacks Equity Research
OPKO's (OPK) subsidiary, BioReference Laboratories, collaborates with the City of Detroit to offer COVID-19 testing.
PRA Health's New Program to Lend Support to Healthcare System
by Zacks Equity Research
PRA Health's (PRAH) COVID-19 Monitoring Program will allow individuals to connect with a healthcare professional remotely while maintaining social distancing.
OPKO's BioReference Laboratories Offers COVID-19 Testing
by Zacks Equity Research
OPKO's (OPK) BioReference Laboratories will initially provide testing for facilities at Burlington, Essex, Hudson, Ocean and Union Counties in New Jersey.
The Zacks Analyst Blog Highlights: Roche, Thermo Fisher Scientific, Becton, Dickinson and Teladoc Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Thermo Fisher Scientific, Becton, Dickinson and Teladoc Health
4 Potential Gainers Amid Intensifying Coronavirus Fears
by Trina Mukherjee
Amid the pandemonium associated with coronavirus, we look into four stocks that have the potential to benefit from this outbreak.
BD (BDX) & BioGX Submit EUA to Speed Up Coronavirus Screening
by Zacks Equity Research
BD (BDX) expects screening to ramp up by 1,000 per day once authorized.
BD MAX Gets CE Mark for Coronavirus Detection, Shares Up
by Zacks Equity Research
BD (BDX) and Spain's CerTest Biotec collaborate to detect the COVID-19 in Europe.
Coronavirus-Affected MedTech Drags S&P 500 Index Down
by Trina Mukherjee
Amid uncertainty surrounding the coronavirus outbreak, here are a few S&P 500 MedTech stocks that took a hit.
Becton Dickinson (BDX) Down 5.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 MedTech Stocks to Rebound After Coronavirus-Led Recoil
by Sriparna Ghosal
As the coronavirus chaos continues to rise, MedTech firms have been witnessing a spike in demand for protective respiratory equipment.
PDCO or BDX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PDCO vs. BDX: Which Stock Is the Better Value Option?
Coronavirus Spreads Rapidly Worldwide: Medtech Stocks in Focus
by Aparajita Dutta
The coronavirus outbreak disrupts manufacturing and supply chain in China, which in turn might have taken a toll on U.S. Medtech stocks.
Bleak Outlook for Medical Dental Supplies Industry
by Sreyoshi Mukherjee
Despite digital dentistry and AI being dominant market trends, near-term prospects of the Dental industry look dull.
New Strong Sell Stocks for February 13th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.
Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.76% and 1.23%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
BD Life Sciences to Aid Becton, Dickinson (BDX) Q1 Earnings
by Zacks Equity Research
BD's (BDX) core Life Sciences arm is expected to have driven first-quarter performance.
Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Becton Dickinson (BDX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to Becton, Dickinson Stock Now
by Zacks Equity Research
Becton, Dickinson (BDX) expects fiscal 2020 revenue growth to be driven by recent product launches.
The Zacks Analyst Blog Highlights: Royal Dutch, TOTAL, Becton, Dickinson, Workday and TransDigm
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Royal Dutch, TOTAL, Becton, Dickinson, Workday and TransDigm
Top Research Reports for Royal Dutch Shell, TOTAL & Becton, Dickinson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Royal Dutch Shell (RDS.A), TOTAL (TOT) and Becton, Dickinson (BDX).